Calibration and refinement of ACMG/AMP criteria for variant classification with

BayesQuantify

Sihan Liu[1,2,*], Xiaoshu Feng[1,2], Fengxiao Bu[1,2,*]

[1] Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
[2] Institute of Rare Diseases, West China Hospital, Sichuan University, Chengdu 610041, China

[*] Correspondence: bufengxiao@wchscu.cn; liusihan@wchscu.cn

Abstract

Background: Improving the precision and accuracy of variant classification in clinical genetic testing requires further specification and stratification of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria. While the Clinical Genome Resource (ClinGen) Bayesian framework enables quantitative evidence calibration for selected criteria, standardized tools to optimize evidence thresholds and systematically refine ACMG/AMP criteria remain underdeveloped.

Methods: To address this gap, we developed *BayesQuantify*, an R package that provides a unified resource for quantifying evidence strength for ACMG/AMP criteria based on the Bayesian framework. *BayesQuantify* accepts a variant classification file as input and automatically calculates the odds of pathogenicity for each evidence strength, incorporating user-provided prior probabilities of pathogenicity. Through bootstrapping, *BayesQuantify* generates thresholds by aligning the 95% lower boundary of positive likelihood ratio/local positive likelihood ratio values with the odds of pathogenicity for different evidence levels. Three independent datasets (the

ClinVar 2019 dataset, the ClinGen curated dataset, and the *PTEN* gene dataset) derived from

ClinVar, HGMD, and gnomAD were utilized to evaluate the utility of *BayesQuantify*.

Results: Validation across three independent datasets demonstrates that *BayesQuantify* delivers

objective, consistent refinements for both categorical and continuous ACMG/AMP evidence.

Specifically, we replicated the PP3/BP4 thresholds for four computational tools (BayesDel,

VEST4, REVEL, and MutPred2) recommended by the ClinGen Sequence Variant Interpretation

Working Group using the ClinVar 2019 dataset. Our analysis also indicated that the PM2 criterion

should be downgraded from moderate to supporting evidence, aligning with ClinGen

recommendations. Importantly, we have established thresholds for supporting, moderate, and

strong evidence for in-silico tools using this tool, thereby expanding the application of PP3/BP4

criteria for missense variants in the *PTEN* gene.

Conclusions: *BayesQuantify* is an accessible and user-friendly resource that enhances the rigor

and reproducibility of ACMG/AMP criteria application. By facilitating evidence-based

stratification and threshold optimization, the tool strengthens variant classification workflows,

offering immediate value to clinical genetic testing laboratories and research communities. The

package is freely available at https://github.com/liusihan/BayesQuantify.

Keywords: ACMG/AMP guidelines, Bayesian framework, Evidence refinement, R package,

Likelihood ratio

Background

Interpreting sequence variants in human genes is a pivotal aspect of diagnosing and managing genetic diseases[1, 2]. However, this task presents considerable challenges due to the complexity and diversity of the genomic data and the lack of standardization and consistency across laboratories[3]. To address these issues, the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) have developed a set of guidelines for variant interpretation, comprising 28 criteria which support or refute the pathogenicity or benignity of a variant[4]. These criteria are grouped into five strength levels of evidence (stand-alone, very strong, strong, moderate, and supporting) and are combined according to specific rules to assign a variant into one of five categories: pathogenic (P), likely pathogenic (LP), uncertain significance (US), likely benign (LB), and benign (B). Since their introduction, the ACMG/AMP guidelines have facilitated the genetic diagnosis of suspected inherited disorders and have become widely adopted by clinical laboratories and researchers as the standard for variant interpretation and reporting[5-8].

In 2018, the ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI) proposed a Bayesian framework that transformed the ACMG/AMP guidelines into a probabilistic system[9]. This framework assumes four levels of evidence and exponentially scaled odds of pathogenicity (OP). It assigns a posterior probability of pathogenicity (Post_P) to a variant by multiplying the OP for each level of evidence (O_{PVSt}, O_{PSt}, O_{PM}, $O_{PSu,}$ O_{BVSt}, O_{BSt}, O_{BM}, O_{BSu}) with a prior probability of pathogenicity (Prior_P). The resulting posterior probability is then compared with probability thresholds to categorize variants: (1) the pathogenic combinations would have Post_P >

0.99, (2) the Post_P of the likely pathogenic combinations would be $0.90 < Post\_P \leq 0.99$, (3) the

Post_P of the likely benign combinations would be $0.001 \leq Post\_P < 0.10$, and (4) the one benign

category would have $Post\_P < 0.001$. By modelling the ACMG/AMP guidelines with a Prior_P of

0.10 and O_{PVSt} set to 350, 15 out of 17 existing ACMG/AMP evidence combinations (except BA1)

were found to be mathematically consistent with the overall framework, validating the approach

adopted by the ACMG/AMP.

The Bayesian framework presents opportunities for refining evidence and combining rules, as well

as supporting efforts to automate components of variant pathogenicity assessments. Researchers

have quantified and extended the strengths of evidence criteria such as PS1/PM5, PS3/BS3, and

PP3/BP4 according to the Bayesian framework[10-16]. Importantly, thresholds for PS4,

PS4_Moderate, and PS4_Supporting have been quantified by aligning positive likelihood ratio

(LR^{+}) and local positive likelihood ratio (lr^{+}) values with theoretical OP for each evidence strength

in our prior study[17]. Our study shows that the refinement of PS4 improves the identification of

pathogenic variants, supporting that the specification and stratification of evidence is essential to

establish an objective, unbiased and consistent variant classification[7, 8, 18]. However, there is a

lack of existing software and tools tailored to quantify the strength of evidence and establish

appropriate thresholds to refine the ACMG/AMP criteria.

In this study, we develop *BayesQuantify*, an R package that undergoes the ClinGen Bayesian

framework for quantifying the strength of evidence for ACMG/AMP criteria. *BayesQuantify*

provides functions to estimate OP for each level of evidence strength and the posterior probability

of pathogenicity for the ACMG/AMP combining rules. Furthermore, *BayesQuantify* facilitates the

calculation of LR^+ and lr^+ for various tested cutoffs, aligning the 95% lower boundary of LR^+/lr^+

with OP to establish thresholds. Additionally, users can employ *BayesQuantify* to classify variants

in accordance with ACMG/AMP combining rules and Bayesian framework, as well as visualize

both the data and statistic results[4, 9]. The *BayesQuantify* is available from GitHub at

https://github.com/liusihan/BayesQuantify.

Methods

BayesQuantify workflow overview

The functions available through *BayesQuantify* were designed to quantify the evidence strength

and thresholds following the algorithm proposed by ClinGen SVI. The package requires one

essential input: a *data.frame* containing variants classification results, including the variants,

ACMG/AMP evidence, variant classification, and tested features (e.g. Table S1 and Table S2). The

step-by-step usage of *BayesQuantify* consists of five main steps as follows (Figure 1):

1. **Step 1: Calculation of OP and Post_P for each evidence strength**: The SVI Working Group

has provided an Excel spreadsheet to calculate Post_P from Prior_P and OP from pathogenic

and benign evidence categories[9]. Based on this spreadsheet, users can manually adjust the

values of Prior_P and O_{PVSt} to obtain the OP values corresponding to each level of evidence

strength. However, this process was computationally inefficient and prone to user bias. To

overcome these limitations, we developed *auto_select_postp*(), a core algorithm in

BayesQuantify, which systematically evaluates O_{PVSt} values over a plausible range (1-10,000)

in combination with user-defined Prior_P values. For each iteration, it calculates Post_P using

Bayes' rule and validates compliance with ACMG/AMP rules for combining evidence and

predefined pathogenicity probability thresholds. The output identifies the minimum O_{PVSt}

value that satisfies these constraints, ensuring robust, reproducible OP and Post_P calculation.

$$OP = O_{PVSt}^{(\frac{N_{PVSt}}{1}+\frac{N_{PSt}}{2}+\frac{N_{PM}}{4}+\frac{N_{PSu}}{8}-\frac{N_{BSu}}{8}-\frac{N_{BM}}{4}-\frac{N_{BSt}}{2}-\frac{N_{BVSt}}{1})}$$

113   (Equation 1)

114   $$Post\_P = \frac{OP * Prior\_P}{((OP - 1) * Prior\_P + 1)}$$

115   (Equation 2)

2. **Step 2: Variants of US (VUS) subclassification:** The majority of human genomic variants are

rare, resulting in a high prevalence of VUS in clinical classifications. To optimize statistical

efficiency and reduce classification bias, we have implemented a systematic approach to

categorize and filter VUS. The *VUS_classify*() function is developed to stratify variants into

six confidence tiers (hot, warm, tepid, cool, cold, ice cold) as defined by the Association for

Clinical   Genomic   Science   (ACGS)   Best   Practice   Guidelines

(https://www.acgs.uk.com/quality/best-practice-guidelines/#VariantGuidelines).   Variants

classified as cool, cold, or ice cold are designated benign-leaning VUS (BL-VUS), whereas

hot, warm, or tepid variants are classified as pathogenic-leaning VUS (PL-VUS). To establish

a robust truth set for refining the evidence criteria, we recommended excluding PL-VUS to

avoid confounding the truth set with ambiguous or potentially pathogenic classifications. This

stratification ensures a high-confidence dataset for calibrating evidence thresholds while

maintaining biological and clinical relevance.

3. **Step 3: Calculating LR⁺/lr⁺:** Within the ClinGen Bayesian framework, the OP quantifies the probability of observing specific evidence if a variant is pathogenic. To quantify evidence thresholds, *BayesQuantify* provided functions to calculate the LR^+/lr^+ using the following methodologies:

For binary variables (e.g. variant marked with PM2 or not): The *LR*() function computes various performance metrics by evaluating the presence or absence of specific evidence among disease-causing and non-pathogenic variants. These metrics include true positive (TP), false positive (FP), true negative (TN), and false negative (FN), overall accuracy, true positive rate (sensitivity), true negative rate (specificity), positive predictive value (PPV), negative predictive value (NPV), F1 score, and LR^+ (equation 3). The 95% confidence interval (CI) for LR^+ is estimated using bootstrapping in the R package bootLR [19]. The lower bound of LR^+ (LR^+_LB) is then utilized to determine evidence strength by comparing it with the OP thresholds generated in Step 1.

$$LR^+ = \frac{TP/(TP + FN)}{1 - TN/(TN + FP)}$$

(Equation 3)

For quantitative variables (e.g. scores from in-silico tools used for tagging PP3/BP4): the *local_bootstrapped_lr()* function first sorts all unique tested cutoffs and positions each cutoff at the center of a user-defined sliding window (default: 0.01). The local posterior probability of pathogenicity and benignity is then calculated for each tested cutoff within the interval, considering a minimum quota of disease-causing and non-pathogenic variants (equation 4).

Additionally, the one-sided 95% confidence bound for each estimated lr^+ is determined through

bootstrapping iterations. The *get_lr_threshold()* function can determine the thresholds for each

evidence level by mapping the lower bound of local posterior probability with the thresholds

generated in Step 1.

Local posterior probability

$$= \frac{\#P/LP \; variants \; in \; interval}{\#P/LP \; in \; interval + (Weight * \#non-pathogenic \; variants \; in \; interval)}$$

(Equation 4)

4. **Step 4: Variant classification:** *BayesQuantify* offers two functions for variant classification:

The *ACMG_Classification*() function categorizes variants into five tiers (P, LP, B, LB, and

VUS) using predefined evidence combinations from the ACMG/AMP guidelines; In parallel,

the *BCF*() function applies to a Bayesian classification framework to classify variants by

calculating posterior probabilities of pathogenicity with user-provided Prior_P and OP for each

evidence level.

5. **Step 5: Visualization:** To improve user-friendliness, *BayesQuantify* includes several

visualization functions: 1) the *multi_plot()* function generates composite plots to display

variant characteristics (e.g., allele frequency, conservation scores) in the input data.frame; 2)

the *heatmap_LR()* function creates heatmaps to visualize the distribution of positive likelihood

ratios across tested cutoffs, highlighting thresholds where LR values meet or exceed OP bounds

for pathogenicity or benignity; and 3) the *plot_lr()* function plots local posterior probability

curves for quantitative variables, showing the distribution of lr^+.

All these steps are implemented within the R programming environment to consolidate all

intermediate data generated throughout the workflow, ensuring transparency and user-friendly

operation. For a detailed explanation of each step with code and examples, see the website of the

package (https://github.com/liusihan/BayesQuantify).

Data sets

The ClinVar 2019 dataset

To evaluate the performance of *BayesQuantify*, the ClinVar 2019 dataset, compiled by Pejaver et

al. was obtained from https://zenodo.org/records/8347415[10]. This dataset includes missense

variants with an allele frequency (AF) below 0.01 in the Genome Aggregation Database (gnomAD

v.2.1) and from genes with at least one pathogenic variant of any type in ClinVar[20]. In total,

11,834 variants (5,705 P/LP and 6,129 B/LB variants) from 1,914 genes are included in this dataset

(Table S1).

The ClinGen Curated Variants dataset

The ClinGen Curated Variants dataset was retrieved from the ClinGen Evidence Repository as of

April 7th, 2024 (https://erepo.clinicalgenome.org/evrepo/). This dataset contains expert-curated

assertions on variant pathogenicity, along with supporting evidence summaries[18]. It includes

classification summaries for 6,768 variants across 74 diseases, with 1,850 P, 1,463 LP, 679 LB,

775 B, and 2,001 US variants (Figure 2 and Table S2). Variants tagged with BA1 were excluded,

resulting in the removal of 664 variants from downstream analysis.

The *PTEN* dataset

To perform the calibration for the *PTEN* gene (MIM# 601728), we constructed a dataset, referred

to as the *PTEN* dataset, which included variants classified as disease-causing and non-pathogenic.

Variants were sourced from three databases: ClinVar (v20241120)[21], HGMD (2024q1)[22], and

gnomAD (v4.1)[20]. These variants were filtered out based on the following criteria: (1) Only

missense variants located in the *PTEN* (NM_000314.8) gene with an AF below 0.01 in gnomAD

were retained; (2) For variants observed exclusively in gnomAD, only those variants annotated as

"PASS" in the "FILTER" column were included; (3) Variants with conflicting pathogenicity

annotations between ClinVar (P/LP) and HGMD (DM/DM?) were excluded; and (4) Variants

classified as uncertain significance or with conflicting classifications in ClinVar were also removed.

Disease-causing variants were defined as P/LP variants, either with a review status of

"criteria_provided,_multiple_submitters,_no_conflicts,", or "reviewed_by_expert_panel," or

those with consistent classifications between ClinVar and HGMD. Non-pathogenic variants were

included variants classified as B/LB variants in ClinVar or rare variants only observed in gnomAD

(Table S3).

Estimation of the prevalence of pathogenic variants for the ClinGen Curated Variants

dataset

To estimate the prevalence of pathogenic variants in the ClinGen Curated Variants dataset, we

performed the following steps to generate a reference dataset from gnomAD: 1) 332,531 variants

were extracted from gnomAD (v4.1), focusing on coding regions of genes with at least one P/LP

variant in the ClinGen Curated Variants dataset; 2) variants with an AF < 0.01 and those annotated

as "PASS" in the "FILTER" column were retained; and 3) P/LP variants present in ClinVar

(v20241120) or HGMD (2024q1) were removed. The final reference dataset consisted of 133,270

potentially non-pathogenic variants. Based on this, we estimated the prevalence of pathogenic

variants in the ClinGen Curated Variants dataset to be 2.48% (3,313/133,270).

Estimation of the prevalence of pathogenic variants for the *PTEN* dataset

For estimating the prevalence of pathogenic variants in the *PTEN* dataset, we utilized a combined

dataset from ClinVar (v20241120), HGMD (2024q1), and gnomAD (v4.1). Variants in the *PTEN*

gene with an AF > 0.01 in gnomAD, as well as those with conflicting pathogenicity annotations

between ClinVar (P/LP) and HGMD (DM/DM?), were excluded. The prevalence of pathogenic

variants in this dataset was found to be 4.68% (1,319/28,171).

Calibration of computational tools in the *PTEN* dataset

To systematically evaluate and calibrate computational tools, we annotated variants using

precomputed prediction scores from the Database of Human Nonsynonymous SNPs (dbNSFP 4.7a)

via the Variant Effect Predictor (VEP) [23, 24]. A total of 38 prediction scores from the dbNSFP

database, covering the entire human genome, were compared. All genomic positions for these

precomputed scores were based on the GRCh38/hg38 reference genome. To standardize the

assessment, we employed a rank score methodology, which scaled the raw prediction scores to a

0-1 range, reflecting the proportion of variants deemed less damaging. The performance of these

38 tools was then evaluated in the *PTEN* dataset using receiver-operating characteristic (ROC)

curves, generated with the R package pROC[25].

Results

Generating OP values and high-confidence datasets using *BayesQuantify*

Comprehensive OP values for ACMG/AMP criteria were established across three distinct datasets

through the *auto_select_postp*() function in *BayesQuantify*. For the ClinVar 2019 dataset

(Prior_P=0.0441, estimated by Pejaver et al.), pathogenic evidence required OP values ≥2.41

(Supporting), ≥5.80 (Moderate), ≥33.65 (Strong), and ≥1132 (Very Strong), while benign evidence

thresholds were ≤0.415, ≤0.172, ≤0.03, and ≤0.001 respectively. The ClinGen Curated Variants

dataset (Prior_P=0.0248) exhibited elevated pathogenic thresholds ($O_{PSu} \geq 2.65$, $O_{PM} \geq 7.06$,

$O_{PSt} \geq 49.9$, $O_{PVSt} \geq 2490$) with corresponding benign thresholds at $O_{BSu} \leq 0.376$, $O_{BM} \leq 0.142$,

$O_{BSt} \leq 0.02$, and $O_{BVSt} \leq 0.0004$. For the *PTEN* dataset, the OP values were: $O_{PSu} \geq 0.384$, $O_{PM} \geq$

5.682, $O_{PSt} \geq 32.28$, $O_{PVSt} \geq 1042$, $O_{BSu} \leq 0.42$, $O_{BM} \leq 0.176$, $O_{BSt} \leq 0.031$, and $O_{BVSt} \leq 0.001$, with

a Prior_P of 0.0468.

To accurately refine the ACMG/AMP criteria, the *VUS_classify()* function was used to categorize

variants of uncertain significance into six levels, generating high-confidence datasets by excluding

PL-VUS variants. In the ClinGen Curated Variants dataset, this approach resulted in 5,137 variants,

comprising 1,847 P, 1,463 LP, 123 B, 673 LB, and 1,031 BL-VUS variants. Correspondingly, the

ClinVar 2019 dataset encompassed 5,705 disease-causing variants and 6,129 non-pathogenic

variants, while the *PTEN* dataset consisted of 326 disease-causing variants and 69 non-pathogenic

variants.

Validating the utility of *BayesQuantify* for evidence refinement and variant classification

To assess the accuracy of *BayesQuantify* in refining evidence for variant classification, we

replicated the calibration of four recommended computational tools (BayesDel, MutPred2, REVEL, and VEST4) using the ClinVar 2019 dataset, as proposed by Pejaver et al. for determining PP3 and BP4 evidence levels. Using 10,000 bootstrap iterations, we calculated local posterior probabilities for each unique score generated by these tools. Our analysis confirmed that all four tools achieved thresholds for strong evidence of pathogenicity (BayesDel $\geq$ 0.53, MutPred2 $\geq$ 0.925, REVEL $\geq$ 0.921, VEST4 $\geq$ 0.96). For benignity, BayesDel ($\leq$ -0.36) and VEST4 ($\leq$ 0.32) reached moderate evidence thresholds, while MutPred2 ($\leq$ 0.02) and REVEL ($\leq$ 0.04) met strong evidence thresholds (Figure 3, Table S4). These results align with Pejaver et al.'s findings, validating the reliability of *BayesQuantify* in evidence calibration.

We further evaluated *BayesQuantify*'s ability to classify variants into five categories (P, LP, B, LB, and VUS) according to the ACMG/AMP guidelines and the Bayesian classification framework. Using the ClinVar 2019 dataset, *BayesQuantify* demonstrated 99.02% concordance (n = 6,702 variants) with existing classifications (Table S5). Of the 66 discordant cases, discrepancies arose from clinical judgement beyond guideline-based evidence. A representative example is the *CDH23* variant NM_022124.6:c.380A>G (p.Asp127Gly), which is classified as a VUS according to the ACMG/AMP criteria. This variant is absent in gnomAD v2.1.1 (PM2_Supporting) and computationally predicted to be deleterious (REVEL = 0.796, PP3). Although detected in an individual with autosomal recessive Usher syndrome (PP4) and confirmed to be in compound heterozygosity with a pathogenic frameshift variant (NM_022124.6:c.1949dup, p.Leu651fs; PM3), its Bayesian posterior probability (0.812) fell below the threshold for likely pathogenic classification ($\geq$ 0.9). Despite this, the ClinGen Hearing Loss Variant Curation Expert Panel

(VCEP) re-evaluated the variant on 18 January 2023 and retained its likely pathogenic designation

based on clinical expertise.

Evaluating the clinical weight of PM2 criteria in variant pathogenicity classification

The 2015 ACMG/AMP guidelines originally defined PM2 as a moderate pathogenic criterion,

applicable when a variant is absent or extremely rare (e.g., recessive conditions) in population

databases such as gnomAD. However, concerns arose about overestimating its predictive value, as

large-scale studies (e.g., ExAC) revealed that 54% of rare variants occurred only once, suggesting

that rarity alone is insufficient to infer pathogenicity. To address this concern, we evaluated the

clinical weight of PM2 criteria using *BayesQuantify*. In the ClinGen Curated Variants dataset, PM2

was designated as moderate evidence and supporting evidence in accordance with gene-/disease-

specific guidelines and emerged as the most frequently applied pathogenic criterion, being utilized

in 3,072 P/LP variants, 580 BL-VUS, and 114 B/LB variants, respectively (Figure S1). We

evaluated whether or not PM2 and PM2_Supporting met the relative odds of pathogenicity for a

Moderate (7.064:1) and Supporting pathogenic (2.658:1) evidence type. Consequently, a total of

3,766 variants were tagged with PM2_Supporting, including 3,072 P/LP variants and 694 BL-

VUS/B/LB variants. The accuracy was 0.819, PPV was 0.816, sensitivity was 0.928, specificity

was 0.620, and LR^+ was 1.497 (95% CI, 1.443–1.555), which was lower than the O_{PSu} value for

the supporting evidence level (Table 1 and Table S6). Furthermore, 1,102 variants were identified

with a moderate evidence level of PM2, comprising 1,002 P/LP variants and 100 BL-VUS/B/LB

variants. However, the accuracy was 0.531, PPV was 0.910, sensitivity was 0.302, specificity was

0.945, and LR^+ was 5.531 (95% CI, 4.575–6.818), reaching the supporting evidence level

($LR^+\_LB \geq 2.658$).

Calibration of in-silico tools for predicting pathogenicity for the *PTEN* gene

We systematically evaluated 38 variant impact prediction algorithms curated in the dbNSFP v4.2a

database to establish calibrated thresholds for *PTEN* missense variant pathogenicity classification,

enhancing precision in clinical interpretation aligned with ACMG/AMP guidelines. The

distribution of prediction scores between non-pathogenic and disease-causing variants in the *PTEN*

dataset across all 38 tools was shown in Figure S2. Twelve tools (SiPhy, phastCons, phyloP,

GERP++, fitCons, GenoCanyon, fathmm_MKL, DANN, LIST_S2, fathmm_XF, MutationTaster,

and LRT) were excluded from downstream analysis due to over-mixed prediction scores for both

non-pathogenic and disease-causing variants. The remaining 26 tools showed an area under the

curve (AUC) values ranging from 0.782 to 0.946 (Figure S3), with the Evolutionary model of

Variant Effect (EVE; AUC =0.946) exhibiting the best performance, followed closely by Rare

Exome Variant Ensemble Learner (REVEL; AUC = 0.945) and Variant Effect Scoring Tool (VEST;

AUC = 0.943).

To assess the clinical utility of these prediction scores for variant curation based on ACMG/AMP

recommendations, we calibrated the top 10 performing tools. The local posterior probability-based

approach proposed by ClinGen SVI allowed for identifying thresholds corresponding to different

levels of evidence. This approach was applied to the following 10 tools: AlphaMissense[26],

BayesDel[27], ClinPred[28], EVE[29], M-CAP[30], MetaLR[31], MetaRNN[32], MVP[33],

REVEL[34], and SIFT[35]. We obtained variant scores from these tools, calculated local posterior

probabilities, and assigned corresponding strengths of evidence based on the thresholds outlined

in Table 1.

We identified thresholds for supporting and moderate evidence of pathogenicity (PP3) and

benignity (BP4) for all tools, except for MetaLR and MVP, which did not yield moderate evidence

for BP4. Interestingly, the local posterior probability curves demonstrated that, at appropriate

thresholds, several tools could provide strong evidence for pathogenicity (ClinPred, M-CAP,

MetaLR, MetaRNN) or benignity (AlphaMissense), as illustrated in Figure 4 and Table 2.

Discussion

The ClinGen Bayesian framework offers a solid mathematical basis for refining ACMG/AMP

criteria within clinical laboratory practice. However, to our knowledge, there is a lack of freely

available software tools that provide similar functionalities for the academic community. In this

article, we present *BayesQuantify*, an R package designed to enhance the flexibility and

convenience of quantifying the strength of evidence and establishing corresponding thresholds for

ACMG/AMP criteria based on the Bayesian framework. It is important to note that while

BayesQuantify is a computational tool, it necessitates human input to ensure the accuracy of its

results. By expanding the evidence base of the ACMG/AMP criteria, *BayesQuantify* has the

potential to elevate the classification of VUS to definitive interpretations.

BayesQuantify offers an objective assessment of whether various forms of evidence align with the

relative weights specified by the Bayesian framework. Our analysis indicated that the PM2

criterion should be downgraded from moderate to supporting evidence, which is consistent with

the ClinGen SVI recommendations (https://clinicalgenome.org/docs/pm2-recommendation-for-

absence-rarity/). This adjustment addresses the historical overestimation of the predictive value of

PM2 as population databases reveal high rates of ultra-rare variants. To mitigate the potential

impact of PM2 downgrading in variant classification, the ClinGen SVI also proposes novel

evidence combinations beyond the 2015 ACMG/AMP guidelines, combining a Very Strong (e.g.

PVS1) and a Supporting criterion (e.g. PM2_Supporting) to achieve a Likely Pathogenic

classification (Bayesian posterior probability=0.988). This approach ensures that novel loss-of-

function variants with strong mechanistic evidence (PVS1) and an adjusted PM2 weight retain

actionable classifications, while mitigating over-reliance on rarity alone.

The Bayesian framework implemented in *BayesQuantify* extends the quantification of evidence

strength from categorical to continuous variables, including computational predictors. We

corroborates Pejaver et al.'s findings, demonstrating that BayesDel, MutPred2, REVEL and

VEST4 achieve strong evidence thresholds for pathogenicity (PP3) and moderate evidence for

benignity (BP4). The slight discrepancies between our results and those of Pejaver et al. can be

attributed to variations in the bootstrap process. Although these findings are applicable across

various genes, a genome-wide approach may mask the heterogeneous performance of predictors

within distinct genes[36, 37]. As such, gene-specific calibrations are crucial for improving

accuracy and precision in variant classification.

Our study attempted to calibrate the PP3 and BP4 criteria for missense variants in the *PTEN* gene,

thereby refining their application in variant classification. Germline pathogenic variants in *PTEN*

are associated with a highly heterogeneous clinical spectrum and are observed in individuals with

conditions such as Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and other

phenotypes, including macrocephaly and autism, collectively referred to as PTEN Hamartoma

Tumor Syndrome[38, 39]. In 2018, the ClinGen PTEN Expert Panel introduced gene-specific

criteria for *PTEN* variant curation, incorporating disease-specific modifications and adjustments

to the strength of evidence across 19 criteria[40]. However, the guidelines did not establish a set

of thresholds for applying PP3 or BP4 criteria to *PTEN* missense variants, leaving a critical gap in

variant interpretation. According to our results, we recommend using MetaRNN or AlphaMissense

to determine evidence for codes PP3 and BP4, as these tools provide strong or moderate evidence

for pathogenicity and benignity[26, 32]. Both tools demonstrated high AUC values (above 0.93),

maximizing the strength of evidence while minimizing false positives in the supporting and

moderate categories. Given the absence of a dedicated validation dataset, future studies are

necessary to validate these thresholds.

A limitation worth discussing is the assumption within the Bayesian framework that each

categorical type of evidence at the same evidence strength level had the same mathematical support.

Given the complexity of interpreting genetic evidence, this simplifying assumption is reasonable

but may not fully capture the nuances involved. Previous studies have identified dependencies and

correlations between evidence rules, such as those observed in BS3/BP4 and PVS1/PP3[41, 42].

To address this limitation, extending the Bayesian framework by estimating more precise evidence

weights using real-world datasets containing true positives and true negatives could provide

greater accuracy. Such methods have already been implemented for some evidence types in genes

related to breast and colorectal cancers[16, 43]. Furthermore, given the potential misclassification

in public databases[44-46], we emphasize the importance of user-curated datasets in refining

evidence when utilizing *BayesQuantify*.

Conclusions

In summary, we have developed *BayesQuantify*, an R package for calibrating and refining ACMG/AMP criteria for variant classification according to the Bayesian framework. This tool is user-friendly and significantly facilitates the shift from a predominantly subjective assessment to a more quantitative and objective approach. By expanding the evidence base of the ACMG/AMP criteria, *BayesQuantify* can enhance the existing ACMG criteria and improve the reclassification of VUSs.

396 **Abbreviations**

ACMG/AMP: American College of Medical Genetics and Genomics/ Association for

Molecular Pathology

*AF: A*llele frequency

B: Benign

BL-VUS: Benign-leaning VUS

CI: Confidence interval

gnomAD: The Genome Aggregation Database

LB: Likely Benign

LP: Likely Pathogenic

LR$^+$: Positive likelihood ratio

lr$^+$: Local positive likelihood ratio

OP: Odds of pathogenicity

O$_{PVSt}$: Odds of pathogenicity for "very strong" evidence

P: Pathogenic

Post_P: Posterior probability of pathogenicity

Prior_P: Prior probability of pathogenicity

VUS: Variants with Uncertain Significance

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The ClinGen Curated Variants data was downloaded from https://erepo.clinicalgenome.org/evrepo/. The ClinVar 2019 set was sourced from https://zenodo.org/records/8347415. The three datasets included in this study are provided in the supplementary tables and are also included in the *BayesQuantify* package.

Competing interests

The authors declare no conflicts of interest.

Funding

This work was supported by the Natural Science Foundation of Sichuan Province, China (Grant No. 2024NSFSC1767), the National Natural Science Foundation of China (Grant No. 82402185 and Grant No. 82171836) and the 1·3·5 project for disciplines of excellence, West China Hospital,

419 Sichuan University (Grant No. ZYJC20002).

Authors' contributions

Acknowledgements

428 We would like to extend a special thanks to Information Center of West China Hospital for

429 technical support. Figure 1 created with BioRender.com.

References

1. Giles HH, Hegde MR, Lyon E, Stanley CM, Kerr ID, Garlapow ME, Eggington JM: **The Science and Art of Clinical Genetic Variant Classification and Its Impact on Test Accuracy**. *Annu Rev Genomics Hum Genet* 2021, **22**:285-307.

2. Marian AJ: **Clinical Interpretation and Management of Genetic Variants**. *JACC Basic Transl Sci* 2020, **5**(10):1029-1042.

3. Pepin MG, Murray ML, Bailey S, Leistritz-Kessler D, Schwarze U, Byers PH: **The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories**. *Genet Med* 2016, **18**(1):20-24.

4. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E *et al*: **Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology**. *Genet Med* 2015, **17**(5):405-424.

5. Niehaus A, Azzariti DR, Harrison SM, DiStefano MT, Hemphill SE, Senol-Cosar O, Rehm HL: **A survey assessing adoption of the ACMG-AMP guidelines for interpreting sequence variants and identification of areas for continued improvement**. *Genet Med* 2019, **21**(8):1699-1701.

6. Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, Berg JS, Biswas S, Bowling KM, Conlin LK *et al*: **Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium**. *Am J Hum Genet* 2016, **98**(6):1067-1076.

7. Patel MJ, DiStefano MT, Oza AM, Hughes MY, Wilcox EH, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J *et al*: **Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss**. *Genet Med* 2021, **23**(11):2208-2212.

8. Amendola LM, Muenzen K, Biesecker LG, Bowling KM, Cooper GM, Dorschner MO, Driscoll C, Foreman AKM, Golden-Grant K, Greally JM *et al*: **Variant Classification Concordance using the ACMG-AMP Variant Interpretation Guidelines across Nine Genomic Implementation Research Studies**. *Am J Hum Genet* 2020, **107**(5):932-941.

9. Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, Biesecker LG, ClinGen Sequence Variant Interpretation Working G: **Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework**. *Genet Med* 2018, **20**(9):1054-1060.

10. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O'Donnell-Luria A, Harrison SM, Tavtigian SV, Greenblatt MS *et al*: **Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria**. *Am J Hum Genet* 2022, **109**(12):2163-2177.

11. Villani RM, McKenzie ME, Davidson AL, Spurdle AB: **Regional-specific calibration enables application of computational evidence for clinical classification of 5' cis-regulatory variants in Mendelian disease**. *Am J Hum Genet* 2024, **111**(7):1301-1315.

12. Brünger T, Ivaniuk A, Pérez-Palma E, Montanucci L, Cohen S, Smith L, Parthasarathy S,

Helbig I, Nothnagel M, May P *et al*: **Pathogenic paralogous variants can be used to apply the ACMG PS1 and PM5 variant interpretation criteria**. *medRxiv* 2023:2023.2008.2022.23294353.

13. Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM, Bis-Brewer D, Cass A, Tchourbanov A *et al*: **Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup**. *Am J Hum Genet* 2023, **110**(7):1046-1067.

14. Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, Kanavy DM, Luo X, McNulty SM, Starita LM *et al*: **Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework**. *Genome Med* 2019, **12**(1):3.

15. Wilcox EH, Sarmady M, Wulf B, Wright MW, Rehm HL, Biesecker LG, Abou Tayoun AN: **Evaluating the impact of in silico predictors on clinical variant classification**. *Genet Med* 2022, **24**(4):924-930.

16. Clark KA, Paquette A, Tao K, Bell R, Boyle JL, Rosenthal J, Snow AK, Stark AW, Thompson BA, Unger J *et al*: **Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions**. *Am J Hum Genet* 2022, **109**(6):1153-1174.

17. Liu S, Zhong M, Huang Y, Zhang Q, Chen T, Xu X, Peng W, Wang X, Feng X, Kang L *et al*: **Quantitative thresholds for variant enrichment in 13,845 cases: improving pathogenicity classification in genetic hearing loss**. *Genome Med* 2023, **15**(1):116.

18. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL *et al*: **ClinGen--the Clinical Genome Resource**. *N Engl J Med* 2015, **372**(23):2235-2242.

19. Marill KA, Chang Y, Wong KF, Friedman AB: **Estimating negative likelihood ratio confidence when test sensitivity is 100%: A bootstrapping approach**. *Stat Methods Med Res* 2017, **26**(4):1936-1948.

20. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP *et al*: **The mutational constraint spectrum quantified from variation in 141,456 humans**. *Nature* 2020, **581**(7809):434-443.

21. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W *et al*: **ClinVar: improving access to variant interpretations and supporting evidence**. *Nucleic Acids Res* 2018, **46**(D1):D1062-D1067.

22. Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD *et al*: **The Human Gene Mutation Database (HGMD((R))): optimizing its use in a clinical diagnostic or research setting**. *Hum Genet* 2020, **139**(10):1197-1207.

23. Liu X, Li C, Mou C, Dong Y, Tu Y: **dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs**. *Genome Med* 2020, **12**(1):103.

24. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F:

The Ensembl Variant Effect Predictor. *Genome Biol* 2016, **17**(1):122.

25. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M: **pROC: an open-source package for R and S+ to analyze and compare ROC curves**. *BMC Bioinformatics* 2011, **12**:77.

26. Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, Pritzel A, Wong LH, Zielinski M, Sargeant T *et al*: **Accurate proteome-wide missense variant effect prediction with AlphaMissense**. *Science* 2023, **381**(6664):eadg7492.

27. Feng BJ: **PERCH: A Unified Framework for Disease Gene Prioritization**. *Hum Mutat* 2017, **38**(3):243-251.

28. Alirezaie N, Kernohan KD, Hartley T, Majewski J, Hocking TD: **ClinPred: Prediction Tool to Identify Disease-Relevant Nonsynonymous Single-Nucleotide Variants**. *Am J Hum Genet* 2018, **103**(4):474-483.

29. Frazer J, Notin P, Dias M, Gomez A, Min JK, Brock K, Gal Y, Marks DS: **Disease variant prediction with deep generative models of evolutionary data**. *Nature* 2021, **599**(7883):91-95.

30. Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, Bernstein JA, Bejerano G: **M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity**. *Nat Genet* 2016, **48**(12):1581-1586.

31. Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X: **Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies**. *Hum Mol Genet* 2015, **24**(8):2125-2137.

32. Li C, Zhi D, Wang K, Liu X: **MetaRNN: differentiating rare pathogenic and rare benign missense SNVs and InDels using deep learning**. *Genome Med* 2022, **14**(1):115.

33. Qi H, Zhang H, Zhao Y, Chen C, Long JJ, Chung WK, Guan Y, Shen Y: **MVP predicts the pathogenicity of missense variants by deep learning**. *Nat Commun* 2021, **12**(1):510.

34. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D *et al*: **REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants**. *Am J Hum Genet* 2016, **99**(4):877-885.

35. Ng PC, Henikoff S: **SIFT: Predicting amino acid changes that affect protein function**. *Nucleic Acids Res* 2003, **31**(13):3812-3814.

36. Brock DC, Wang M, Hussain HMJ, Rauch DE, Marra M, Pennesi ME, Yang P, Everett L, Ajlan RS, Colbert J *et al*: **Comparative analysis of in-silico tools in identifying pathogenic variants in dominant inherited retinal diseases**. *Hum Mol Genet* 2024, **33**(11):945-957.

37. Tejura M, Fayer S, McEwen AE, Flynn J, Starita LM, Fowler DM: **Calibration of variant effect predictors on genome-wide data masks heterogeneous performance across genes**. *Am J Hum Genet* 2024, **111**(9):2031-2043.

38. Mester J, Eng C: **When overgrowth bumps into cancer: the PTEN-opathies**. *Am J Med Genet C Semin Med Genet* 2013, **163C**(2):114-121.

39. Yehia L, Keel E, Eng C: **The Clinical Spectrum of PTEN Mutations**. *Annu Rev Med* 2020, **71**:103-116.

40. Mester JL, Ghosh R, Pesaran T, Huether R, Karam R, Hruska KS, Costa HA, Lachlan K, Ngeow J, Barnholtz-Sloan J *et al*: **Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel**. *Hum Mutat* 2018, **39**(11):1581-1592.

41. Kanavy DM, McNulty SM, Jairath MK, Brnich SE, Bizon C, Powell BC, Berg JS: **Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels**. *Genome Med* 2019, **11**(1):77.

42. Garrett A, Durkie M, Callaway A, Burghel GJ, Robinson R, Drummond J, Torr B, Cubuk C, Berry IR, Wallace AJ *et al*: **Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations**. *J Med Genet* 2021, **58**(5):297-304.

43. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ *et al*: **A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes**. *Am J Hum Genet* 2007, **81**(5):873-883.

44. Wright CF, Eberhardt RY, Constantinou P, Hurles ME, FitzPatrick DR, Firth HV, Study DDD: **Evaluating variants classified as pathogenic in ClinVar in the DDD Study**. *Genet Med* 2021, **23**(3):571-575.

45. Sharo AG, Zou Y, Adhikari AN, Brenner SE: **ClinVar and HGMD genomic variant classification accuracy has improved over time, as measured by implied disease burden**. *Genome Med* 2023, **15**(1):51.

46. Shah N, Hou YC, Yu HC, Sainger R, Caskey CT, Venter JC, Telenti A: **Identification of Misclassified ClinVar Variants via Disease Population Prevalence**. *Am J Hum Genet* 2018, **102**(4):609-619.

 Figures

Figure 1: Schematic overview of *BayesQuantify*. *BayesQuantify* begins with the input of variant

classification results dataset. Subsequently, it computes the positive likelihood ratio (LR^+) and

local positive likelihood ratio (lr^+), which are then aligned with predefined odds of pathogenicity

(OP) for each evidence strength to refine evidence. Prior_P: prior probability of pathogenicity;

Post_P: posterior probability of pathogenicity.

Figure 2: Characteristics of the 6,768 variants in the ClinGen Curated Variants dataset. (a) Summary of classification for the 6,768 variants. (b) Further subclassification of variants of uncertain significance (VUS) to hot, warm, tepid, cool, cold, and ice-cold groups, according to the ACGS Best Practice Guidelines. Variants categorized as "cool/cold/ice cold" were defined as benign-leaning VUS (BL-VUS), while those classified as "hot/warm/tepid" were defined as pathogenic-leaning VUS (PL-VUS). (c) Distribution of pathogenic (P) and likely pathogenic (LP) variants across the top twenty genes.

Figure 3: Local posterior probability curves of pathogenicity and benignity for various BayesDel, VEST4, REVEL and MutPred2 scores in the ClinVar 2019 dataset. The horizontal lines depict the posterior probability thresholds for supporting, moderate, strong, and very strong evidence. The black curves represent the posterior probability estimated from ClinVar 2019 dataset, while the grey curves represent one-sided 95% confidence intervals calculated from 10,000 bootstrap samples of this dataset.

Figure 4: Local posterior probability curves ten in-silico tools in the *PTEN* dataset. The horizontal lines depict the posterior probability thresholds for supporting, moderate, strong, and very strong evidence. The black curves represent the posterior probability estimated from *PTEN* dataset, while the grey curves represent one-sided 95% confidence intervals calculated from 10,000 bootstrap samples of this dataset. The points at which the gray curves intersect the horizontal lines represent the thresholds for the relevant intervals.

Table 1: Posterior probability and positive likelihood ratio values corresponding to each evidence strength in the three datasets included in this study.

Evidence Strength	ClinGen Curated Variants dataset		ClinVar 2019 dataset		PTEN dataset	
	OP	Posterior probability	OP	Posterior probability	OP	Posterior probability
PVS	2490	0.985	1132	0.981	1042	0.981
PS	49.90	0.560	33.645	0.608	32.28	0.613
PM	7.064	0.153	5.800	0.211	5.682	0.218
PP	2.658	0.064	2.408	0.100	2.384	0.105
BP	0.376	0.990	0.415	0.981	0.420	0.980
BM	0.142	0.996	0.172	0.992	0.176	0.991
BS	0.020	0.999	0.030	0.999	0.031	0.998
BVS	0.0004	1.000	0.001	1.000	0.001	1.000

666 Table 2: Estimated threshold ranges corresponding to the four pathogenic and four benign intervals
667 for the *PTEN* gene.

Method	Benign (BP4)				Pathogenic (PP3)			
	Very Strong	Strong	Moderate	Supporting	Supporting	Moderate	Strong	Very Strong
AlphaMissense	-	≤ 0.060	(0.060, 0.453]	(0.453, 0.643]	[0.935, 0.974)	≥ 0.974	-	-
BayesDel	-	-	≤ 0.638	(0.638, 0.794]	[0.908, 0.925)	≥ 0.925	-	-
ClinPred	-	-	≤ 0.447	(0.447, 0.564]	[0.836, 0.917)	[0.917, 0.999)	≥ 0.999	-
EVE	-	-	≤ 0.324	(0.324, 0.385]	[0.567, 0.668)	≥ 0.668	-	-
M-CAP	-	-	≤ 0.686	(0.686, 0.883]	[0.967, 0.973)	[0.973, 0.998)	≥ 0.998	-
MetaLR	-	-	-	≤0.907	[0.965, 0.983)	[0.983, 0.999)	≥ 0.999	-
MetaRNN	-	-	≤ 0.581	(0.581, 0.745]	[0.949, 0.976)	[0.976, 0.986)	[0.986, 0.987)	≥ 0.987
MVP	-	-	-	≤ 0.912	[0.980, 0.985)	≥ 0.985	-	-
REVEL	-	-	≤ 0.744	(0.744, 0.865]	[0.959, 0.972)	≥ 0.972	-	-
SIFT	-	-	≤ 0.328	(0.328, 0.440]	[0.722, 0.785)	≥ 0.785	-	-